Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
JCSE 01.24 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
11:30 - 11:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-032 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
09:30 - 09:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.07 - A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
11:40 - 11:45 | Presenter: Aaron Lisberg | Author(s): J. Hunt, N. Reese, T. Wang, P. Coluzzi, M. Spiegel, K. Bornazyan, J. Carroll, J. Madrigal, B. Ledezma, M. Mendenhall, J.L. Bui, H. Lu, A. Cummings, Z. Noor, Jonathan W. Goldman, Edward Brian Garon
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.01 - First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
15:45 - 15:55 | Presenter: Yi-Long Wu | Author(s): Ying Cheng, X. Zhou, K.H. Lee, Kazuhiko Nakagawa, Seiji Niho, F. Tsuji, Rafael Rosell, J. Corral, M.R. Migliorino, A. Pluzanski, R. Linke, E.I. Sbar, T. Wang, H. Zhang, Tony SK Mok
- Abstract
Loading...
-
+
OA 07 - Biomarker for Lung Cancer
- 15:45 - 17:30
- 10/16/2017
- Location: Room 503
- Type: Oral
- Track: Biology/Pathology
- Moderators:Philip Christopher Mack, Shinichi Toyooka
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-012 - Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study
09:30 - 09:30 | Presenter: Rickard Sandin | Author(s): M.R. Migliorino, Tony SK Mok, Yi-Long Wu, X. Zhou, K.H. Lee, Kazuhiko Nakagawa, Seiji Niho, F. Tsuji, R. Linke, Rafael Rosell, J. Corral, A. Pluzanski, E.I. Sbar, A. Reisman, T. Wang, J.L. White, Ying Cheng
- Abstract
Loading... -
+
P3.01-072 - Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa | Author(s): F. Ohyanagi, Terufumi Kato, T. Takahashi, H. Kaneda, N. Nogami, Seiji Niho, N. Yamamoto, Y. Fujita, H. Zhang, E.I. Sbar, T. Wang, R. Linke, F. Tsuji, Tony SK Mok
- Abstract
Loading...